We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · September 17, 2021

IASLC WCLC 2021: Nivolumab and Ipilimumab Plus Chemotherapy Beneficial for Advanced Non–Small Cell Lung Cancer With or Without Brain Metastases

Findings support benefit of this combination for first-line therapy in advanced disease

PracticeUpdate Editorial Team


Further Reading